**FOI Ref: 6326**

**Category(ies): Clinical - Drugs**

**Subject: Lung Cancer Treatment**

**Date Received: 01/04/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:* Afatinib
* Alectinib
* Atezolizumab monotherapy
* Atezolizumab in combination
* Bevacizumab
* Brigatinib
* Capmatenib
* Ceritinib
* Crizotinib
* Dacomitinib
* Dabrafenib with Trametinib
* Docetaxel monotherapy
* Durvalumab
* Erlotinib
* Gefitinib
* Gemcitabine
* Nintedanib with Docetaxel
* Nivolumab
* Osimertinib
* Paclitaxel
* Pembrolizumab monotherapy
* Pembrolizumab in combination
* Pemetrexed with Carboplatin/Cisplatin
* Tepotinib
* Vinorelbine with Cisplatin/Carboplatin
* Any other SACT
* Palliative care only
 | Regarding Palliative care only. 0 – Zero patients.Systemic Anti-Cancer Therapy for Lung cancer patients is delivered by Weston Park; therefore, we are unable to further answer this request. The request would need to go to Sheffield Teaching Hospitals who can be contacted via email at sth.foi@nhs.net  |